Q1178_flexicam_1_5_mgm.1_8.tp

Dechra Veterinary Products
(A business unit of Dechra
Pharmaceuticals PLC)
Cartmel Drive
Harlescott
Shrewsbury SY1 3TB
Tel: 01743 441632
FLEXICAM 1.5 MG/ML ORAL SUSPENSION FOR
Contra-indications, warnings, etc
Do not use in animals suffering from gastrointesti- Presentation
nal disorders, such as irritation and haemorrhage, suspension for dogs contains 1.5 mg meloxicam as impaired hepatic, cardiac or renal function, and active ingredient (equivalent to 0.05 mg per drop).
haemorrhagic disorders, or where there is evidence Alleviation of inflammation and pain in both of individual hypersensitivity to the product.
acute and chronic musculoskeletal disorders.
Do not use in dogs less than 6 weeks of age.
Dosage and administration
If side effects occur, treatment should be discontin- single dose of 0.2 mg meloxicam/kg body weight on ued and the advice of a veterinarian should be sought.
the first day. Treatment is to be continued once daily Avoid use in any dehydrated, hypovolaemic or hypo- by oral administration (at 24 hour intervals) at a tensive animal, as there is a potential risk of increased maintenance dose of 0.1 mg meloxicam/kg body Other NSAIDs, diuretics, anticoagulants, aminogly- Shake well before use. To be administered mixed coside antibiotics and substances with high protein binding may compete for binding and thus lead to The suspension can be given using either the drop toxic effects. Flexicam must not be administered in dispenser (for very small breeds) or the Flexicam conjunction with other NSAIDs or glucocorticoster- measuring syringe provided in the package.
The dispenser provides 0.05 mg Meloxicam per Pre-treatment with anti-inflammatory substances drop (i.e. a dose of 0.1 mg Meloxicam/kg body weight may result in additional or increased adverse effects corresponds to 2 drops/kg body weight). The syringe and accordingly a treatment-free period with such fits onto the bottle and has a kg - body weight scale drugs should be observed for at least 24 hours before which corresponds to the maintenance dose (i.e. 0.1 commencement of treatment. The treatment-free mg/kg body weight). Thus, for the first day, twice the period, however, should take into account the phar- maintenance volume will be required.
macokinetic properties of the products used previ- Dosing procedure using the measuring syringe: 1. Shake bottle well. Push down and unscrew bottle In case of overdosage, symptomatic treatment top. Attach the dosing syringe to the bottle by gently pushing the end onto the top of the bottle.
Adverse reactions: Typical adverse drug reactions 2. Turn the bottle/syringe upside down. Pull the of NSAIDs such as loss of appetite, vomiting, diar- plunger out until the black line on the plunger rhoea, faecal occult blood and apathy have occasion- corresponds to your dog’s body weight in kilograms.
ally been reported. These side effects occur generally 3. Turn the bottle the right way up and with a within the first treatment week and are in most cases twisting movement, separate the dosing syringe from transient and disappear following termination of the treatment, but in very rare cases may be serious or 4. By pushing the plunger in, empty the contents of If you notice any other side effects, please inform A clinical response is normally seen within 3-4 days. Treatment should be discontinued after 10 days Operator warnings: People with known hypersen- at the latest if no clinical improvement is apparent.
sitivity to NSAIDs should avoid contact with the Avoid introduction of contamination during use.
Particular care should be taken with regard to the In case of accidental ingestion, seek medical advice accuracy of dosing. Please carefully follow the in- immediately and show the package insert or label to General precautions: For animal treatment only.
Packaging Quantities
ing 10 ml, 32 ml or 100 ml with a polyethylene Pharmaceutical precautions
dropper, a tamper-proof child resistant closure and a Do not use after the expiry date stated on the carton Further information
Shelf life of opened bottle: 9 months.
Services UK Limited, Langhurstwood Road, Hor- Disposal: Any unused product or waste material derived from such veterinary medicinal productsshould be disposed of in accordance with local Marketing authorisation number EU/2/06/058/001 -
Legal category POM-V
Requested by: kate.gittins@dechra.com
Approved datasheets found: 1
Creation date: 30/9/2008 14:24:24 (UK)
Approved for book but not on website: 0
Datasheets marked as draft (ignored): 0

Source: http://www.serolf.com/professionalline/animalhealth/pomedication/DECHRA/FlexicamUKdatasheet.pdf

Biographical sketch

BIOGRAPHICAL SKETCH Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2. Follow this format for each person. DO NOT EXCEED FOUR PAGES. Cong. John E. Porter Professor of Microbiology-Immunology; Director, Immunobiology Center EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, su

Biographical sketch

BIOGRAPHICAL SKETCH Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2. Follow this format for each person. DO NOT EXCEED FOUR PAGES. Cong. John E. Porter Professor of Microbiology-Immunology; Director, Immunobiology Center EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, su

Copyright © 2010-2014 Online pdf catalog